Table 2.
The incidence of different groups of de novo antibodies in patients in SF and SB immunosuppression
| De novo Abs | SF (n=60) | SB (n=64) | P Value (Titer) | Total (n=124) | ||
|---|---|---|---|---|---|---|
| Number (%) | Average Titer | Number (%) | Average Titer | |||
| Class 1 | 2 (3%) | 6130 | 3 (5%) | 12,970 | 0.44 | 5 (4%) |
| Class 2 | 1 (2%) | 6383 | 1 (2%) | 13,835 | 2 (2%) | |
| Cw, DQ, and DP | 6 (10%) | 5894 | 10 (16%) | 7348 | 0.51 | 16 (13%) |
| NDSA | 4 (7%) | 3823 | 5 (8%) | 8705 | 0.15 | 9 (7%) |
| DSA | 3 (5%) | 6214 | 4 (6%) | 13,829 | 0.08 | 7 (6%) |
| MICA | 4 (7%) | 9512 | 3 (5%) | 21,762 | 0.05 | 7 (6%) |
There are some trend differences in DSA and MICA in the SF and SB groups, but the number of events is too small in each arm to reach significance.